These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 421216)

  • 41. New derivatives of CNC-amino acids and -oligopeptides: experimental antitumor activity.
    Zeller WJ
    J Cancer Res Clin Oncol; 1986; 111(2):154-6. PubMed ID: 3700459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice.
    Hayat M; Bourut C; Chenu E; Montero JL; Imbach JL; MacDonald JS; Mathé G
    Cancer Chemother Pharmacol; 1979; 3(4):217-21. PubMed ID: 161207
    [No Abstract]   [Full Text] [Related]  

  • 43. A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice.
    Panasci LC; Green D; Nagourney R; Fox P; Schein PS
    Cancer Res; 1977 Aug; 37(8 Pt 1):2615-8. PubMed ID: 141323
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state.
    Maral R; Bourut C; Chenu E; Mathe G; Bernon R; Lussan C; Imbach JL; Schein P; Bothorel P
    Oncology; 1985; 42(2):122-8. PubMed ID: 3157909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis of nitrosourea derivatives of sucrose as central nervous system anticancer agents.
    Almquist RG; Reist EJ
    J Med Chem; 1977 Oct; 20(10):1246-50. PubMed ID: 903916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and antitumor activity of N-terminal proline-containing peptide-(chloroethyl)nitrosoureas.
    Süli-Vargha H; Jeney A; Lapis K; Medzihradszky K
    J Med Chem; 1987 Mar; 30(3):583-6. PubMed ID: 3820230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specific protection against the cytotoxicity of a new class of nitrosoureas by pyrimidine deoxyribonucleosides.
    Fischer PH; Lin TS; Chen MS; Prusoff WH
    Biochem Pharmacol; 1979 Oct; 28(19):2973-8. PubMed ID: 518693
    [No Abstract]   [Full Text] [Related]  

  • 48. Nitrosoureidonucleosides.
    Montgomery JA; Thomas HJ
    J Med Chem; 1979 Sep; 22(9):1109-13. PubMed ID: 490557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. QSAR in cancer chemotherapy.
    Hansch C
    Farmaco Sci; 1979 Jan; 34(1):89-104. PubMed ID: 399923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In the search for new anticancer drugs, XXI. Spin labeled nitrosoureas.
    Sosnovsky G; Li SW; Rao NU
    Z Naturforsch C J Biosci; 1987; 42(7-8):921-31. PubMed ID: 2961152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the role of isocyanates in the action of therapeutic nitrosoureas.
    Hilton J; Maldarelli F; Sargent S
    Biochem Pharmacol; 1978 May; 27(9):1359-63. PubMed ID: 567992
    [No Abstract]   [Full Text] [Related]  

  • 52. In the search for new anticancer drugs. XXIII: Exploration of a predictive design for anticancer drugs of carbohydrates containing N-nitrosochloroethylamino, N-nitrosomethyl, and N-nitrosoaminoxyl components.
    Sosnovsky G; Rao NU
    J Pharm Sci; 1991 Jul; 80(7):693-9. PubMed ID: 1658297
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
    Johnston TP; McCaleb GS; Clayton SD; Frye JL; Krauth CA; Montgomery JA
    J Med Chem; 1977 Feb; 20(2):279-90. PubMed ID: 836500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of mutagenicity tests in screening chemical carcinogens.
    Montesano R
    Prog Biochem Pharmacol; 1978; 14():157-62. PubMed ID: 347453
    [No Abstract]   [Full Text] [Related]  

  • 55. Mutagenicity of a series of N-alkyl-, N-hydroxyalkyl-, N-haloalkyl- and N-carboxyalkyl-N-nitrosoureas in Escherichia coli tester strains: dependence on the uvrA DNA-repair system.
    Kohda KH; Ninomiya S; Washizu K; Shiraki K; Ebie M; Kawazoe Y
    Mutat Res; 1987 Apr; 177(2):219-28. PubMed ID: 3031494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Commentary. The role of structure-activity studies in the design of antitumor agents.
    Cain BF
    Cancer Chemother Rep; 1975; 59(4):679-83. PubMed ID: 1175161
    [No Abstract]   [Full Text] [Related]  

  • 57. The mutagenicity of nitrosamides in Salmonella typhimurium.
    Lijinsky W; Andrews AW
    Mutat Res; 1979 Sep; 68(1):1-8. PubMed ID: 386106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Some antitumor derivatives of ellipticine deprived of mutagenic properties.
    Lecointe P; Lesca P; Cros S; Paoletti C
    Chem Biol Interact; 1978 Jan; 20(1):113-21. PubMed ID: 630641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ergot alkaloids. Synthesis of nitrosourea derivatives of ergolines as potential anticancer agents.
    Crider AM; Lu CK; Floss HG; Cassady JM; Clemens JA
    J Med Chem; 1979 Jan; 22(1):32-5. PubMed ID: 423180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In the search for new anticancer drugs. XXII: Synthesis and anticancer evaluation of some dipeptides containing N-nitrosochloroethylamino and chloroethylamino moieties.
    Sosnovsky G; Rao NU
    J Pharm Sci; 1990 Apr; 79(4):369-70. PubMed ID: 2352153
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.